Endoron Medical Raises $10M to Accelerate Validation of AAA EndoStapling Solution

Endoron Medical, a pioneering medtech firm specializing in innovative endograft stapling solutions for abdominal aortic aneurysms (AAA), has successfully closed a $10 million Series A funding round. Sofinnova Partners led the round, with substantial contributions from the European Innovation Council Fund (EIC Fund).

The funding will expedite the clinical validation of Endoron’s flagship product, the catheter-based EndoStapling solution Aortoseal, as it progresses through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS).

Ronit Harpaz, co-founder and CEO of Endoron, commented, “Sofinnova Partners are renowned investors within medtech, bringing valuable operational experience from high-growth companies like ours. With their support, we’re poised to achieve critical clinical and regulatory milestones as we advance our EndoStapling technology toward market readiness. The EIC’s participation further underscores our dedication to introducing this innovative solution in Europe.”

Endoron is pioneering advancements in endovascular AAA repair technology, addressing challenges in sealing and securing endografts used in minimally invasive procedures, particularly for complex cases. Its innovative stapling mechanism ensures secure anchoring and complete sealing of endografts, aiming to prevent migration and reduce complications that necessitate invasive surgeries.

Cécile Dupont, Partner at Sofinnova Partners’ medtech accelerator MD Start, stated, “Endoron exemplifies Sofinnova Partners MD Start’s strategy of accelerating promising innovations at early stages. We believe Endoron’s EndoStapling technology has transformative potential in AAA repair, and we’re thrilled to support their journey.”

Svetoslava Georgieva, Chair of the EIC Fund Board, added, “We’re pleased to contribute to Endoron’s funding round. Our investment aims to advance their endovascular repair solution, potentially reducing complications and improving patient outcomes.”

With this funding, Endoron is well-positioned to capitalize on the growing market demand for innovative endovascular care solutions. The company remains committed to advancing endovascular repair technologies to enhance patient care and outcomes.

About Endoron Medical:
Founded in 2019, Endoron Medical is led by a team of industry experts including Ronit Harpaz, Prof. Ron Karmeli, and Eyal Teichman. They bring extensive experience in healthcare innovation and are dedicated to improving endovascular repair solutions.

About Sofinnova Partners:
Sofinnova Partners is a leading European venture capital firm focused on life sciences and sustainability. Based in Paris, London, and Milan, the firm supports entrepreneurs throughout the life sciences investment journey, from seed funding to later-stage development, to drive transformative innovations for a better future.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter